Every week, we put a spotlight on one of the DigitalHealth.London Accelerator or Launchpad companies. Here’s a roundup of this month’s featured SMEs:
About: A platform in secondary care, designed by Clinicians, that digitally enhances Outpatient clinics, creating efficiencies, improved patient & clinical satisfaction and enhanced clinical outcomes.
Recent success: Our COVID-19 response has meant Acute Myocardial Infarction (AMI) patients can be discharged after 1-2 days compared with 3-5 days through close remoting monitoring, questionnaires and video follow-up appointments, reducing potential exposure to COVID-19 infection.
We have also been able to bulk on-board 273 Gastrointestinal Cancer patients into a digital pathway instantly triggering SMS messages to securely notify patients of the change saving hours of physically calling patients of the change.
Ask: Introductions to NHSX, CCIO and CIOs who aspire to cement virtual clinics beyond COVID-19 by understanding limitations of video/telephone only digital outpatient solutions; namely a solution encompassing appointment management, initial assessments and remote monitoring.
Contact: firstname.lastname@example.org (Dr Debashish Das, CEO)
About: We provide exercise training, support and education for people living with cancer. We work with patients referred to us privately both one-to-one and in groups. We also work with NHS trusts to help incorporate exercise into the treatment pathway for prostate cancer patients as well as other cancers.
Recent success: Winning the support and funding from a leading cancer hospital in London for the design and implementation our one-year behaviour change exercise pilot including use of our App.
Ask: Introductions to healthcare professionals with a particular interest in helping cancer patients engage in exercise.
About: We are making cardiovascular surgeries safer and more accurate.
Recent success: Our technology, PreSize Neurovascular, was recently CE marked as a medical device for use by interventional neuroradiologists in the planning of brain stenting surgeries.
Ask: More hospital trial sites to run pilots of PreSize Neurovascular with us, in the process participating in a pioneering initiative to improve patient outcomes for high risk surgical procedures.
Contact: email@example.com (Katerina Spranger is Oxford Heartbeat’s founder and CEO)